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Brussels, Belgium
BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid
leukemia, inducing deep molecular responses, largely improving patient survival and
rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs,
dasatinib, nilotinib, and ponatinib, increase the risk of developing arterial thrombosis. Prior
investigations reported that nilotinib and ponatinib affect the endothelium, but the
mechanisms by which they exert their toxic effects are still unclear. The impact of
dasatinib and bosutinib on endothelial cells has been poorly investigated. Here, we
aimed to provide an in vitro homogenous evaluation of the effects of BCR-ABL TKIs on the
endothelium, with a special focus on the type of cell death to elucidate the mechanisms
responsible for the potential cytotoxic effects of BCR-ABL TKIs nilotinib and ponatinib on
endothelial cells. We tested the five BCR-ABL TKIs at three concentrations on human
umbilical venous endothelial cells (HUVECs). This study highlights the endothelial toxicity
of ponatinib and provides insights about the mechanisms by which it affects endothelial
cell viability. Ponatinib induced apoptosis and necrosis of HUVECs after 72 h. Dasatinib
affected endothelial cells in vitro by inhibiting their proliferation and decreased wound
closure as soon as 24 h of treatment and even at infra-therapeutic dose (0.005 µM).
Comparatively, imatinib, nilotinib, and bosutinib had little impact on endothelial cells at
therapeutic concentrations. They did not induce apoptosis nor necrosis, even after 72 h of
treatment but they inhibited HUVEC proliferation. Overall, this study reports various effectsin.org July 2020 | Volume 11 | Article 10071
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Frontiers in Pharmacology | www.frontiersof BCR-ABL TKIs on endothelial cells and suggests that ponatinib and dasatinib induce
arterial thrombosis through endothelial dysfunction.Keywords: BCR-ABL tyrosine kinase inhibitor, chronic myeloid leukemia, endothel ial cel ls,
atherosclerosis, cardiovascularINTRODUCTION
Since the approval in 2001 of imatinib, the first tyrosine kinase
inhibitor (TKI) targeting BCR-ABL, the interest and use of BCR-
ABL TKIs have continued to grow (Bhamidipati et al., 2013). The
discovery of imatinib led to a revolution in the treatment of
chronic myeloid leukemia (CML), providing strong and durable
molecular responses in numerous patients and improving
patient survival close to that of the general population (Iqbal
and Iqbal, 2014). However, intolerance and resistance to imatinib
arose, leading to the development and approval of dasatinib,
nilotinib, and bosutinib, three second-generation BCR-ABL
TKIs that are nevertheless less selective for BCR-ABL than
imatinib (Gorre et al., 2001; Bixby and Talpaz, 2009). These
three drugs were approved for second-line treatment at the time
of their approval. However, because of their efficacy in inducing
deeper molecular remission, an essential criterion for treatment
cessation (i.e., BCR-ABL1 transcript below 0.01% for at least 2
years), they have been approved for the treatment of chronic-
phase CML in first line (Brummendorf et al., 2015; Cortes et al.,
2016; Hochhaus et al., 2016; National Comprehensive Cancer
Network, 2019). Ponatinib was developed as a fifth BCR-ABL
TKI (Cortes et al., 2012). Because of its efficacy against T315I-
mutated BCR-ABL, a mutation that confers resistance to all
other BCR-ABL TKIs (Cortes et al., 2012), this third generation
drug is used to treat CML resistant to first line treatments.
Altogether, the five drugs are the mainstay of CML treatment
(National Comprehensive Cancer Network, 2019).
Although these treatments are highly effective for CML in
chronic phase, three of them (dasatinib, nilotinib, and ponatinib)
increase the risk of adverse vascular events, particularly the risk
of arterial thrombosis associated to myocardial infarction, stroke,
and peripheral artery disease (Cortes et al., 2015; Pasvolsky et al.,
2015; Douxfils et al., 2016; Haguet et al., 2017). However, each
BCR-ABL TKI exhibits a different clinical vascular safety profile,
suggesting different mechanisms of pathogenesis. The most
common adverse vascular events associated to dasatinib are
pleural effusion and pulmonary arterial hypertension (Cortes
et al., 2017), whereas arterial thrombosis occurs less frequently
(Saglio et al., 2017; Valent et al., 2017). Nilotinib causes
hyperglycemia and hypercholesterolemia in addition to arterial
thrombosis (Racil et al., 2013; Rea et al., 2014), whereas
ponatinib is the TKI associated with the highest arterial
thrombotic risk (Haguet et al., 2018). Interestingly, the time-
to-event (i.e., the time between the initiation of the treatment and
the occurrence of arterial thrombosis) differs between molecules.
Ponatinib is associated with a rapid development of vascular
events (median time-to-event: 8.5–14.1 months), compared to
nilotinib (median time-to-event: 19.0–47.0 months), whereasin.org 2little is known concerning arterial thrombosis induced by
dasatinib (Gagnieu et al., 2013; Cortes et al., 2015; Fossard
et al., 2016; Minson et al., 2019). Even if adverse vascular
events occur more frequently in patients with prior
cardiovascular risk factors, they also affect patients with no
attributable cardiovascular risk factors (Aichberger et al., 2011;
Tefferi and Letendre, 2011). Conversely, it has been proposed
that imatinib prevents the occurrence of such events (Kadowaki
and Kubota, 2004), whereas bosutinib apparently presents a safer
vascular profile than the other second generation TKIs (Valent
et al., 2017).
Because of the wide implementation of second generation
TKIs for chronic patient treatment, their long-term safety is of
particular interest. Understanding the pathophysiology of
adverse vascular events induced by dasatinib, nilotinib, and
ponatinib could help to define suitable risk minimization
measures and help in the selection of the first-line treatment
for CML patients. To date, the mechanisms underlying vascular
adverse events are not fully characterized. Several hypotheses have
been set forward based on the clinical characteristics of the
vascular events. In particular, the predominance of arterial
events raised concerns about the impact of BCR-ABL TKIs on
platelet functions, endothelial cells, and atherosclerosis, and
excluded prothrombotic states to be responsible for these events
(Fossard et al., 2016). However, prior investigation indicated that
BCR-ABL TKIs have no or anti-aggregation effects on platelets,
suggesting a low probability of the implication of platelets in the
occurrence of vascular thrombosis (Haguet et al., 2018). Therefore,
researches focused on endothelial cells and atherosclerosis.
Previous mechanistic studies interrogating the effect of BCR-
ABL TKIs on the vasculature demonstrated that some of these
treatments affect the endothelium. For ponatinib and nilotinib,
an increasing amount of evidence indicates that their vascular
toxicity is a consequence, at least partially, of their effect on
endothelial cells. In vitro, they both decreased endothelial cell
viability and promoted the expression of molecular patterns
related to apoptosis and angiogenesis (Hadzijusufovic et al.,
2017; Gover-Proaktor et al., 2018). For these reasons, it has
been hypothesized that vascular endothelial cells could be at the
very origin of vasculopathies induced by ponatinib and nilotinib,
which would be responsible for direct endothelial dysfunction
(Hadzijusufovic et al., 2017). Dasatinib has been tested
essentially on pulmonary endothelial cells in order to elucidate
the mechanism behind dasatinib-induced pulmonary
hypertension. It induced apoptosis and increased reactive
oxygen species (ROS) reactive oxygen species production by
pulmonary endothelial cells (Guignabert et al., 2016).
Comparatively, the viability of dasatinib-treated endothelial
cells other than pulmonary was unchanged (Gover-ProaktorJuly 2020 | Volume 11 | Article 1007
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toxicity of BCR-ABL TKI is due to their lack of specificity toward
BCR-ABL. Indeed, all BCR-ABL TKIs also inhibit numerous
kinases (Rix et al., 2007; Talbert et al., 2015).
There is a lack of homogeneity in the in vitro studies
performed to investigate the effects of nilotinib and ponatinib
on endothelial cells. Overall, the methods, the tested
concentrations and the cell line used often differed, making
arduous the comparison between studies and resulting in
conflicting reports (Vrekoussis et al., 2006; Venalis et al., 2009;
Katgi et al., 2015). Here, we aimed to provide a homogenous
evaluation and comparison of the viability of endothelial cells
exposed to each of the five commercially available BCR-ABL
TKIs. Major endothelial functions, such as ROS generation, the
expression of adhesion molecules, and migration, have also been
assessed, given their implication in vascular homeostasis and
atherosclerosis. A particular consideration has been paid to
results with dasatinib and bosutinib, as their impact on
endothelial cells had previously been barely investigated, to the
exception of dasatinib on pulmonary endothelial cells. In
addition, even if the impact of nilotinib and ponatinib on
endothelial cells is now well considered, there is still shadow
on the mechanism(s) by which they exert their cytotoxic effects.
To contribute to a better knowledge of the pathophysiology, our
study further aimed to clarify the mechanism(s) by which BCR-
ABL TKIs impair endothelial cell survival in vitro.MATERIALS AND METHODS
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from Lonza (Verviers, Belgium). Cells were cultured
in endothelial cell growth basal medium (Lonza, CC-3121,
Verviers, Belgium) supplemented with SingleQuots™ (Lonza,
CC-4133, Verviers, Belgium) and maintained at 37°C in a
humidified atmosphere containing 5% CO2. HUVECs were
used at passages 2–5.
Drugs
Imatinib mesylate, dasatinib, nilotinib, bosutinib, and ponatinib
were from Absource Diagnostic (Munich, Germany). All
experiments were carried out using clinically relevant TKI
concentrations (50 nM, 500 nM, and 5 µM for imatinib, 5 nM,
50 nM, and 500 nM for dasatinib and ponatinib, and 20 nM, 200
nM, and 2 µM for nilotinib and bosutinib). These concentrations
were selected to consider the binding of TKIs to plasma proteins.
Thus, these concentrations reflect the free concentration of TKIs
in patients taking 400 mg OD of imatinib, 100 mg OD of
dasatinib, 400 mg BID of nilotinib, 500 mg OD of bosutinib,
and 45 mg OD of ponatinib (Table 1) (Rivera et al., 2014).
All experiments were performed in 10% dialyzed FBS from
Thermo Fischer Scientific (Waltham, MA, USA) in order to
minimize interactions with serum-associated proteins, unless
indicated otherwise.Frontiers in Pharmacology | www.frontiersin.org 3Viability
Cell metabolic integrity and viability were assayed using MTS
(Promega, Fitchburg, MA, USA) and LDH (Roche, Basel,
Switzerland) kits, respectively. In brief, HUVECs were seeded in
96-well plates at a density of 2,500 cells/cm2. Four days after
plating, cells were treated with a TKI or 0.2% DMSO (control)
diluted in medium containing 10% dialyzed FBS. Cell metabolic
integrity and viability were assessed after 24 and 72 h of treatment
using MTS and LDH assays according to manufacturers’
instructions. The absorbance at 490 nm was measured with a
SpectraMax ID3 (Molecular Devices, San Jose, CA, USA).
Apoptosis
To assess apoptosis induced by BCR-ABL TKIs, HUVECs were
stained with Annexin V-FITC (staining of phosphatidylserine)
and 7-AAD (DNA staining) in accordance with manufacturer’s
instructions (Abcam, Cambridge, UK). Briefly, HUVECs were
plated in 12-well plates and exposed to a TKI or 0.2% DMSO
(control) for 24 or 72 h. Cells were then stained with Annexin V-
FITC and 7-AAD in binding buffer. Stained HUVECs were
analyzed on a FACS verse flow cytometer (BD Bioscience,
Franklin Lakes, NJ, USA). Early apoptotic (i.e., cells with
externalized phosphatidylserine but with preserved membrane
integrity) and late apoptotic/necrotic cells (i.e., cells with
disrupted plasma membrane integrity) were counted based on
the relative number of Annexin V-FITC+/7-AAD- and 7-AAD+
cells, respectively, using the BD FACSuite® software.
Proliferation
Cell proliferation was assessed using the Click-it 5-ethynyl-2’-
deoxyuridine (EdU) flow kit (Thermo Fisher Scientific). In
addition to the staining of EdU, a DNA stain was added
(FxCycle Violet stain, Thermo Fisher Scientific). Aphidicolin
at 10 µM was used as a positive control (Sigma-Aldrich, Saint-
Louis, MO, USA). Briefly, HUVECs were plated in 12-well
plates and exposed to a TKI, 0.2% DMSO (control), or
aphidicolin. After 24 or 72 h of incubation, EdU was added
for 2 h. Cells were then fixed, permeabilized, and the EdU
detection mix was added for 30 min at room temperature.
Finally, DNA was stained by incubating cells with FxCycle
Violet stain for 30 min. HUVECs were then analyzed by flow
cytometry (BD FACSverse), based on the fact that cells in S-
phase are those that incorporate EdU (FITC+) and cells in G0/
G1 phase and in G2/M phase do not incorporate EdU but are
FxCycle− and FxCycle+, respectively. Data were analyzed using
the BD FACSuite® software.
Reactive Oxygen Species Concentrations
After the exposure of HUVECs to one of the five TKIs or to 0.2%
DMSO (control) for 72 h, ROS content was quantified using CM-
H2DCFDA (Invitrogen, Carlsbad, CA, USA), following
manufacturer’s instructions. The oxidized fluorescent product
retained inside cells was quantified using the FACSverse flow
cytometer. Data were analyzed using the BD FACSuite® software.
SIN-1 hydrochloride (Sigma-Aldrich) was used a positive control.July 2020 | Volume 11 | Article 1007
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Endothelial cell migration was evaluated by a scratch assay that
monitors the ability of cells to migrate in a wound. HUVECs
were cultured in 24-well plates until confluence, and were then
pre-treated with a given TKI or 0.2% DMSO (control) inFrontiers in Pharmacology | www.frontiersin.org 4medium containing 1% FBS (to minimize the contribution of
cell proliferation on scratch closure) or 10% FBS during 24 h.
The confluent monolayer was scratched with a pipette tip, and
wound closure dynamics were tracked using an inverted Leica
DMi1 microscope (Weltzar, Germany). Pictures were capturedTABLE 1 | Summary of the findings of the impact of BCR-ABL TKIs on endothelial cells in vitro.
Imatinib Dasatinib Nilotinib Bosutinib Ponatinib
Clinically effective
Cmax*
0.682 µM 0.072 µM 0.171 µM 0.209 µM 0.040 µM
Assay Measured
parameters
Endothelial cells exposed to BCR-ABL TKIs for 24 h
MTS assay Mitochondrial activity = = = = ↘ (0.5 µM)
LDH assay LDH release
(membrane integrity)
↘ (0.05 µM) = = = ↗ (0.05 µM)
Apoptosis assay Early apoptosis = = = = =
Late apoptosis/
necrosis
= = = = =




↘ (2 µM) ↘↘↘ (2 µM) =
Adhesion molecule
expression (ELISA)
ICAM-1 = ↘ (0.5 µM) ↘ (2 µM) ↘ (0.02 µM)
↗ (2 µM)
↘ (0.005 µM; 0.05
µM)
↘↘↘ (0.5 µM)
VCAM-1 ↘ (0.5 µM) ↘ (0.5 µM) ↘ (2 µM) = ↘ (0.005 µM; 0.05
µM)
↘↘↘↘ (0.5 µM)
E-/P-selectin = ↘ (0.5 µM) = = ↘ (0.5 µM)
Endothelial cells exposed to BCR-ABL TKIs for 72 h
MTS assay Mitochondrial activity ↗ (5 µM) ↗ (0.005 µM;
0.5 µM)
= = ↘↘ (0.5 µM)





0.05 µM; 0.5 µM)
↗↗ (0.02 µM; 0.2 µM;
2 µM)





Apoptosis assay Early apoptosis = ↘↘ (0.005 µM;
0.05 µM; 0.5 µM)
= ↘↘ (2 µM) ↗↗↗↗ (0.5 µM)
Late apoptosis/
necrosis
= = = = ↗↗↗ (0.05 µM)
Proliferation assay Cells in S-phase ↘ (0.05 µM) = ↘ (0.02 µM)
↘↘ (2 µM)
↘↘ (0.2 µM) =
ROS assay ROS levels = = = = =July 2020 | VolumThis table summarizes the results obtain in this study. Only statistically significant differences are reported. The number of arrows represents the magnitude of the following of difference: ↘
(from 0 to −24%),↘↘ (from −25 to −49%),↘↘↘ (from −50 to −74%), and↘↘↘↘ (from −75 to −100%) and↗ (from 0 to 24%),↗↗ (from 25 to 49%),↗↗↗ (from 50 to 74%), and↗↗↗↗ (from
75 to 100%). The concentrations that significantly differed from the control are indicated in brackets.
*Clinically effective Cmax represents the Cmax corrected for the functional effects of protein binding (Rivera et al., 2014).
Cmax, maximum serum concentration.e 11 | Article 1007
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using the Leica Application Suite software version 4.7 to quantify
the extent of cell migration in the cell-free scratch.
On-Cell ELISA
The expression of intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-1), and E-/P-selectin
was measured by on-cell enzyme-linked immunosorbent assay
(ELISA). Briefly, HUVECs were cultured in 96-well plates and
exposed to a TKI or 0.2% DMSO (control) for 24 h. Cells were
then activated with TNF-a (R&D Systems, Minneapolis, MN,
USA) at 10 ng/ml for 4 h. After treatment, cells were fixed with
0.025% glutaraldehyde for 10 min, and blocked with PBS-BSA
1% for 2 h. Fixed cells were incubated overnight with monoclonal
antibodies targeting human ICAM-1 (recombinant human
ICAM-1 clone #14C11, R&D systems), VCAM-1 (recombinant
human VCAM-1 clone #HAE-2Z, R&D systems), and E-/P-
selectin (CD62E/P, clone #BBIG-E6, R&D systems), and finally
incubated with a secondary horseradish peroxidase (HRP)-
conjugated antibody for 1 h (mouse IgG HRP-conjugated
antibody, R&D systems). After incubation with 100 µl of the
HRP substrate (50 µl of hydrogen peroxide and 50 µl of
tetramethylbenzidine; R&D systems) for 20 min, optical
density was measured at 450 nm with an Infinite® M200 PRO
(Tecan, Mechelen, Belgium). Results are expressed as the mean
of the absorbance values relative to control.
Statistical Analyses
Results are expressed as the means of the differences between the
treated value and the control ± standard error of the mean
(SEM). All experiments were repeated independently at least
three times (N = 3). Comparison between different conditions
was performed using the Wilcoxon signed rank test for
experiments for which a standard distribution could not be
defined. For flow cytometry analyses, a one-sample t-test was
used. All statistical analyses were performed using the Prism 8
software (GraphPad Software Inc., San Diego, CA, United
States). Data that were statistically significant in comparison toFrontiers in Pharmacology | www.frontiersin.org 5controls are indicated with * (p < 0.05), ** (p < 0.01) or ***
(p < 0.001).
RESULTS
Impact of BCR-ABL TKIs on Endothelial
Cell Viability
To test the cytotoxicity of BCR-ABL TKIs, HUVECs were exposed
to three different concentrations of imatinib mesylate, dasatinib,
nilotinib, bosutinib, or ponatinib for 24 or 72 h. Cell metabolic
activity was tested using a MTS assay that reports on the activity of
mitochondrial reductases (Buttke et al., 1993). Ponatinib exposure
decreased cell metabolism after 24 and 72 h of treatment, whereas
the other BCR-ABL TKIs did not (Supplementary Figure 1A and
Figure 1A). Rather, HUVECs exposed to imatinib at 5 µM and
dasatinib at 5 and 50 nM increased their metabolism. To link these
results to cell viability, we performed a LDH assay that measures
the leakage of LDH, an intracellular enzyme that is released from
cells upon cell membrane damaged. After 24 h of treatment, TKIs
did not induce more LDH release than control, to the exception of
ponatinib at 0.05 µM that increased LDH release, suggesting that
BCR-ABL TKIs do not induce early cell membrane damage
(Supplementary Figure 1B). However, after 72 h of treatment,
HUVECmembrane integrity was impacted, as shown by increased
LDH release with all BCR-ABL TKIs (Figure 1B). Surprisingly,
this alteration did not depend on the TKI concentration in the
range that we tested.
Because MTS and LDH assays do not fully discriminate the
different cell death modes and to clarify the mechanism(s) by
which BCR-ABL TKIs impair endothelial cell survival, we next
tested apoptosis and late apoptosis/necrosis using specific FACS
assays. After 24 h of incubation, TKIs did not induce apoptosis or
late apoptosis/necrosis (Supplementary Figure 2). However,
after 72 h, ponatinib dose-dependently induced HUVEC
apoptosis and necrosis (Figure 2). Interestingly, dasatinib at all
concentrations and bosutinib at 2 µM reduced the number of
apoptotic cells. The other BCR-ABL TKIs did not significantly
modulate HUVEC apoptosis nor necrosis.A B
FIGURE 1 | All BCR-ABL TKIs induce HUVEC membrane damage after 72 h. MTS (A) and LDH (B) assays were performed on HUVECs exposed for 72 h to the
indicated BCR- ABL TKI in medium with 10% dialyzed FBS. Data are presented as means ± SEM of n = 9 of three independent experiments (N = 3). Results are
expressed relative to control (DMSO 0.2%). Differences between conditions were tested using the Wilcoxon signed rank test that compared the effect of each TKI
condition versus control. *p < 0.05 and **p < 0.01.July 2020 | Volume 11 | Article 1007
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HUVECs as early as 24 h after treatment, as shown by a decreased
of number of cells in the S-phase and an increased number of cells
in the G0-G1 phase (Figure 3), suggesting that these drugs block
HUVEC progression from G1 to S. Responses were dose-
dependent, but they were seen only at the highest, supra-
therapeutic concentrations of imatinib, nilotinib, and bosutinib.
Bosutinib differed from the other TKIs in that, at the highest
concentration, it also increased cells in the G2-M phase (Figure 3).
Imatinib had the slightest effect on endothelial cell proliferation.
After 72 h of treatment, inhibition of proliferation was still
detected in HUVECs exposed to imatinib, nilotinib, and
bosutinib (Supplementary Figure 3).
To complete the investigation of the mechanism by which
BCR-ABL TKIs impact endothelial cell viability, we evaluated
their impact on ROS levels. ROS concentration in HUVECs was
not significantly modified by BCR-ABL TKIs (Figure 4).
Endothelial Cell Migration
As endothelial cell migration is essential for wound healing and
tissue regeneration, the ability of endothelial cells to migrate after
treatment with the TKIs was evaluated by scratch assays. Assays
were first performed in media containing 1% FBS to minimize
the effects of cell proliferation on wound closure. In these
conditions, there was no statistically significant difference
between HUVECs treated with a TKI compared to control
(Supplementary Figure 4). The absence of effect was possibly
due to the high variability of the measurements due to the fact
that scratch closure was slow with reduced cell proliferation.
When we repeated the assay in media containing 10% FBS,
dasatinib, even at infra-therapeutic concentration (0.005 µM)
and bosutinib at high-dose (2 µM) inhibited scratch closure,
whereas nilotinib facilitated wound healing (Figure 5 and
Supplementary Figure 5).Frontiers in Pharmacology | www.frontiersin.org 6Adhesion Molecule Expression
Leukocyte recruitment is an important process in atherogenesis
(Galkina and Ley, 2007). It requires the expression of adhesion
molecules by activated endothelial cells. Here, we assessed in
HUVECs the expression of ICAM-1, VCAM-1, and E-/P-
selectin, three adhesion molecules involved in monocyte/
macrophage recruitment (Čejková et al., 2016). Decreased
expression of all three adhesion molecules was observed in
HUVECs treated with dasatinib, nilotinib, and ponatinib at
high concentrations for 24 h (0.5, 2, and 0.5 µM, respectively;
Figure 6). Imatinib and bosutinib had no or little impact on
adhesion molecule expression.DISCUSSION
Our study demonstrates that BCR-ABL TKIs impact endothelial
cells differently in vitro (Table 1). Ponatinib is the most cytotoxic
for endothelial cells and induces apoptosis and necrosis, whereas
the others BCR-ABL TKIs inhibited HUVEC proliferation. In
addition, dasatinib and bosutinib delayed wound closure. These
findings correlate with their clinical vascular safety profile (Aghel
et al., 2017), and could explain why ponatinib is the BCR-ABL
TKI that induces arterial occlusion the most frequently.
To our knowledge, the present study is the first to report that
dasatinib affects endothelial cells from a different origin than
pulmonary, indicating that the effect of dasatinib is not peculiar
to pulmonary endothelial cells (Guignabert et al., 2016). Dasatinib
inhibited endothelial cell proliferation at all the doses that we
tested, and delayed wound closure. The comparison of the results
of the scratch assay in the presence of 1% versus 10% FBS supports
the hypothesis that delayed wound closure is the consequence of
an inhibition of cell proliferation rather than an impact on
endothelial cell migration. However, prior experiments suggestedA B
FIGURE 2 | Ponatinib induces HUVEC apoptosis and necrosis. HUVECs were labeled with Annexin VFITC and 7-AAD after exposure to BCR-ABL TKIs for 72 h in
medium with 10% dialyzed FBS. The percentage of Annexin V+/7-AAD− and 7-AAD+ cells revealed early apoptotic (i.e., cells exposing phosphatidylserine but with
preserved membrane integrity) (A) and late-apoptotic/necrotic (i.e., cells with disrupted membrane integrity) (B) HUVECs, respectively. Bars represent the means of
three experiments ± SEM. Results are expressed relative to control (DMSO 0.2%). Differences between conditions were tested using a one sample t-test that
compared each TKI condition versus control. *p < 0.05 and **p < 0.01.July 2020 | Volume 11 | Article 1007
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of the actin cytoskeleton and by inhibiting the formation of
intercellular contacts (Dasgupta et al., 2017; Kreutzman et al.,
2017). This impact on the endothelial cell cytoskeleton occurs
through a disruption of the inhibitory signals from integrins to
RhoA, a pathway implicating numerous tyrosine kinases, leading
to RhoA/ROCK pathway activation. However, implicated tyrosine
kinase(s) has/have not yet been identified. Interestingly, dasatinibA
B
C
FIGURE 3 | All BCR-ABL TKIs inhibit HUVEC proliferation. Cell cycle analysis
was performed on HUVECs exposed to BCR-ABL TKIs for 24 h in medium
with 10% dialyzed FBS by measuring EdU incorporation and DNA content
(FxCycle). Histograms represent cells in S-phase (A), G0/G1 phase (B), and
G2/M phase (C). Bars represent the means of the three experiments ± SEM.
Three concentrations were tested for each TKI. Results are expressed relative
to control (DMSO 0.2%). Differences between conditions were tested using a
one sample t-test that compared each TKI condition versus control. *p < 0.05
and **p < 0.01.FIGURE 4 | BCR-ABL TKIs do not increase the ROS levels in HUVECs. ROS
levels in HUVECs after treatment with BCR-ABL TKIs for 72 h in medium with
10% dialyzed FBS, expressed as intensity of FITC. Bars represent the means
of three experiments ± SEM. Results are expressed relative to control (DMSO
0.2%). Differences between conditions were tested using a one sample t-test
that compared each TKI condition versus control.FIGURE 5 | Dasatinib and bosutinib reduce wound closure. HUVEC
migration was assessed by a scratch test after exposure of the cells to BCR-
ABL TKIs for 24 h in 10% FBS media to avoid cell death due to serum-free
conditions. Histograms represent wound closure 6 h after the scratch. Bars
represent the means ± SEM of n = 6 of three independent experiments (N =
3). Differences between conditions were tested using the Wilcoxon signed
rank test that compared each TKI condition versus control. *p < 0.05.July 2020 | Volume 11 | Article 1007
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number of pathways by which dasatinib affects endothelial cell
viability. In addition to its effects on endothelial cell proliferation
and migration, dasatinib increased LDH release after 72 h of
treatment, without inducing necrosis. This suggests that dasatinib
does not induce endothelial cell death, but potentially induces cell
damage. Interestingly, dasatinib protected cells against apoptosis
and increased their metabolism, in accordance with the literature
(Gover-Proaktor et al., 2018). This could explain why dasatinib is
associated with a lower rate of arterial thrombosis than nilotinib
and ponatinib.
Our results confirm the toxicity of ponatinib toward endothelial
cells, endorsing the hypothesis that ponatinib would facilitate
atherosclerosis and arterial thrombosis through alteration of
endothelial cell viability (Katgi et al., 2015; Gover-Proaktor et al.,
2016; Hadzijusufovic et al., 2017; Gover-Proaktor et al., 2018).
Indeed, cell death within the arterial wall has already been
recognized in atherosclerosis. Our study further provides insights
about the mechanisms by which ponatinib dose-dependently affects
endothelial cell viability. Ponatinib induced necrosis without
increasing ROS levels, and might participate in atherosclerosis by
this way (Paez-Mayorga et al., 2018). The identification of the type
of endothelial cell death induced by ponatinib supports at least two
hypotheses regarding the molecular signaling pathways responsible
for this effect. One hypothesis would link necrotic cell death to a
blockade of the cell cycle by the TKIs during progression fromG1 to
S phase. Interestingly, previous in vitro investigation reported a cell
cycle arrest in the G1 phase in liver cancer cells treated with
ponatinib, and identified that this cell cycle blockade was
mediated by a reduction in the function of the CDK4/CDK6/
Cyclin D1 complex (Liu et al., 2019). This complex is regulated
by the prosurvival PI3K/Akt pathway, known to be impacted by
some BCR-ABL TKIs, including ponatinib (Talbert et al., 2015).
Therefore, future researches should analyze the effects of BCR-ABL
TKIs on CDK4, CDK6, and Cyclin D1 levels/activities, and identify
the implicated signaling pathways. A second hypothesis would link
ponatinib-induced cell necrosis to Akt inhibition. Indeed, Akt is also
highly implicated in the regulation of apoptosis signaling and
mediates the responses of a majority of growth factors (Somanath
et al., 2006), and ponatinib is known to inhibit Akt in
cardiomyocytes (Singh et al., 2019). These observations highlight
the need of a further thorough evaluation of this pathways in the
endothelial response to ponatinib.
Interestingly, nilotinib had distinct impact on HUVECs. It
increased LDH release after 72 h, but did not induce necrosis nor
apoptosis at the tested concentrations, suggesting induction of non-
fatal cell damage. It decreased HUVEC proliferation, but without
affecting wound closure. These results are in line with the literature,
and suggest a different etiology of vascular events. Othermechanisms
than endothelial dysfunction with nilotinib should be explored.
Because of its association with the development of hyperglycemia
and hypercholesterolemia, accelerated atherosclerosis has been
proposed as a potential mechanism of vascular thrombosis (Rea
et al., 2014; Damrongwatanasuk and Fradley, 2017). However, it is
currently unknown if the induction of these metabolic disorders
alone is sufficient to explain the vascular complications associatedA
B
C
FIGURE 6 | BCR-ABL TKIs do not increase adhesion molecule expression on
HUVECs. Expression of ICAM-1 (A), VCAM-1 (B), and E-selectin and P-selectin
(C) by HUVECs after a 4-h activation by 10 ng/ml of TNF-a followed by a 24 h
treatment with BCR-ABL TKI in medium without FBS. Data are presented as
means of the absorbance ± SEM of n = 9 of three independent experiments
(N = 3). Three concentrations were tested for each TKI. Results are expressed
relative to control (DMSO 0.2%). Differences between conditions were tested
using the Wilcoxon signed rank test. *p < 0.05 and **p < 0.01.July 2020 | Volume 11 | Article 1007
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artery spasms (Fiets et al., 2018).
Our work confirmed the little impact of imatinib on endothelial
cells, in accordance with the literature (Vrekoussis et al., 2006;
Hacker et al., 2007; Venalis et al., 2009; Gover-Proaktor et al., 2016;
Guignabert et al., 2016; Sukegawa et al., 2017). Even if imatinib did
not induce apoptosis nor necrosis, it increased the release of LDH
after 72 h of treatment, suggesting the induction of non-fatal cell
damage, similarly than with dasatinib and nilotinib. Bosutinib had
little impact on endothelial cells. Yet, similarly to imatinib, it
induced LDH release without inducing cell death, also suggesting
the induction of cell damage. Interestingly, at high concentration (2
µM), it presented a profile close to that of dasatinib, as it inhibited
cell proliferation, retarded wound closure and decreased apoptosis.
Understanding the molecular pathways involved in endothelial cell
death with therapy is important to develop more specific therapies.
To anticipate the occurrence of such events and bring sufficient care
to the vascular safety of new TKIs in clinical trials, in vitro
endothelial testing of new drugs should be a requirement. Non
clinical testing should include in vitro methods for assessing cell
death, because global assays (such as the MTS and the LDH assays)
may generate false-positive results and are not able to discriminate
between cytotoxic and antiproliferative effects (Mery et al., 2017).
The dose-dependent response seen here in most of the tests also
suggests that the choice of the dose is important for in vitro
experiments. This is one of the parameters that varied the most
between studies, explaining most of the discrepancies between
them. Of further note, numerous studies evaluated BCR-ABL
TKIs in vitro using non-clinically relevant concentrations, thus
leading to results that are not pertinent to clinical settings. One
example is the report by Hadzijusufovic et al. that showed increased
ICAM-1, VCAM-1 and E-selectin expression in HUVECs upon a
7.5 µM nilotinib treatment (Hadzijusufovic et al., 2017), whereas
doses of nilotinib from 0.02 µM to 2 µM reduced the expression of
the same protein (this study). Another important parameter that
should be considered when designing the testing of compounds on
endothelial functions in vitro is their binding to serum proteins,
which would directly affect their biodisponibility.PERSPECTIVES AND CONCLUSIONS
This study demonstrates that the responses of endothelial cells
are different according to the TKI, corroborating the difference of
their clinical vascular safety profiles. There are limitations to our
study in that the findings are limited to one cell line (HUVECs).
Even if this cell type is a good model for atherosclerotic studies
(Onat et al., 2011), key observations should be confirmed on
endothelial cells from other origin (e.g., HCAEC) and using more
elaborated models (e.g., models involving vascular functions).
BCR-ABL TKIs should also be tested on other cell lines than
endothelial cells to assess if they would modulate other
physiological functions. In addition, different time of TKI
treatment should be tested, particularly for the assessment ofFrontiers in Pharmacology | www.frontiersin.org 9adhesion molecule expression as Hadzijusufovic et al. reported
increased in ICAM-1 and VCAM-1 cell surface levels after 4 h of
nilotinib treatment (Hadzijusufovic et al., 2017).
To ascertain the relevance of these findings to human, it will
be interesting to evaluate endothelial biomarkers in patients
treated with BCR-ABL TKIs and to address their predictability.
Circulating endothelial cells, endothelial progenitor cells and
endothelial microparticles are good candidate biomarkers. They
are measurable by blood sampling and have already been
associated with damaged endothelium, as well as to predict the
outcome of ischemic vascular diseases (Sabatier et al., 2009;
Thomson and Garbuzova-Davis, 2016). In this context, Gover-
Proaktor et al. suggested that endothelial progenitor cells may be
more sensitive to ponatinib than mature endothelial cells,
possibly because of a their stronger dependence on prosurvival
factors and/or on the different penetration of ponatinib within
the cells (Gover-Proaktor et al., 2016).
Our in vitro-based study analyzed the effects of BCR-ABL TKIs
on endothelial cells with a special focus on cell death. It reports
various effects of BCR-ABL TKIs on endothelial cells, suggesting a
possible multifactorial cause and the possible implication of
several off-targets in the development of cardiovascular events.
Future researches should focus on the study of the molecular
mechanisms that are responsible for endothelial cell death or
impaired cell proliferation with BCR-ABL TKIs. Among the five
commercialized BCR-ABL TKIs, ponatinib showed the most
effects on endothelial cells. It reduced endothelial cell viability by
inducing apoptosis and necrosis, which possibly facilitates the
development of atherosclerosis through impaired endothelium
permeability, enabling cell migration and the trapping of
lipoproteins in the intima. Additionally, we found that dasatinib
inhibits endothelial cell proliferation and can reduce endothelial cell
migration, whichmight contribute to arterial thrombosis formation.
Because of the chronic use of these treatments, long-term
safety is an important issue, and understanding the impact of
these treatments may help in the design of new therapies. It may
be of interest in the conception of strategies aiming at
minimizing the risk of adverse events, i.e., by avoiding the use
of certain therapies in patients with pre-existing impairments in
pathways disturbed by these therapeutic agents.DATA AVAILABILITY STATEMENT
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